Curcumin Supplementation Lowers TNF-α, IL-6, IL-8, and MCP-1 Secretion in High Glucose-Treated Cultured Monocytes and Blood Levels of TNF-α, IL-6, MCP-1, Glucose, and Glycosylated Hemoglobin in Diabetic Rats

Jain, Sushil K.; Rains, Justin; Croad, Jennifer L.; Larson, Bryon W.; Jones, Kimberly L.

doi:10.1089/ars.2008.2140

Cited by 251 publications

(160 citation statements)

References 64 publications

(72 reference statements)

Supporting

Mentioning

148

Contrasting

Unclassified

Order By: Relevance

“…Our study showed that strong reduction in serum and tissue IL-6, with the use of combination treatment, more than each medication alone while curcumin alone showed a significant reduction than irbesartan and STZ group which was in agreement with the data obtained from Aggarwal and Harikumar [35] and Jain et al, [36]. The highly significant reduction observed with combination group may be explained by the presence of a synergistic effect between curcumin and irbesartan.…”

Section: Discussionsupporting

confidence: 92%

Effect of Curcumin and Angiotensin II Receptor Antagonist on Insulin Sensitivity and on Inflammation in Induced Diabetic Rats

Nassar¹,

Mansour²,

Abd‐Allah³

et al. 2017

J Invest Biochem

View full text Add to dashboard Cite

Objective: In this study, we aimed to discuss the effect of curcumin and/or irbesartan on diabetic complications in induced diabetic rats. Materials and Methods: Diabetic rats induced by intraperitoneal injection of 45 mg/kg dose of streptozotocin (STZ) in adult rats. Rats were divided into six groups of 10 rats on each. Serum glucose, creatinine, and urea were estimated using a colorimetric method. Serum insulin and serum and kidney homogenate interleukin 6 (IL-6) were measured using enzyme-linked immunosorbent assay technique. While paraffin-embedded kidney and pancreas specimens were performed for histopathological examination. While homeostasis model assessment of insulin resistance (HOMA-IR) was calculated. Results: Curcumin and/or irbesartan reduce the degradation of kidneys and pancreatic tissues as indicated in both histopathology and tissue IL-6. They improve the weight loss and IR. In addition, they lower circulating level of IL-6, serum creatinine, and urea. Diabetic rats received the medications show significantly better insulin and glucose levels as compared to STZ group. Conclusion: Chronic administration of curcumin and/or irbesartan for diabetic rats decreased serum glucose and HOMA-IR and lowered the increased serum levels of pro-inflammatory cytokines. Using such combination could be beneficial in diabetic managements, especially if diabetes accompanied with hypertension.

show abstract

Section: Discussionsupporting

confidence: 92%

Effect of Curcumin and Angiotensin II Receptor Antagonist on Insulin Sensitivity and on Inflammation in Induced Diabetic Rats

Nassar¹,

Mansour²,

Abd‐Allah³

et al. 2017

J Invest Biochem

View full text Add to dashboard Cite

show abstract

“…Curcumin, however, has been shown to down-regulate TNF expression (Jin et al, 2007;Lee et al, 2007;Zhang et al, 2008;. In addition to being induced by LPS, TNF is also upregulated by a variety of other stimuli including phorbol ester, palmitate and other inflammatory cytokines, and curcumin has been shown to block the expression of TNF induced by all of these stimuli (Abe et al, 1999;Lee et al, 2007;Jain et al, 2009;Wang et al, 2009).…”

Section: Suppression Of Tnf-a Production By Curcumin In Vitromentioning

confidence: 99%

“…• Inhibited the high glucose-induced secretion of IL-6, IL-8, MCP-1 and TNF-a in U937 monocytes (Jain et al, 2009). …”

Section: Production Of Tnfmentioning

confidence: 99%

Curcumin: an orally bioavailable blocker of TNF and other pro‐inflammatory biomarkers

Aggarwal

Gupta

Sung

2013

British J Pharmacology

319

235

View full text Add to dashboard Cite

TNFs are major mediators of inflammation and inflammation-related diseases, hence, the United States Food and Drug Administration (FDA) has approved the use of blockers of the cytokine, TNF-a, for the treatment of osteoarthritis, inflammatory bowel disease, psoriasis and ankylosis. These drugs include the chimeric TNF antibody (infliximab), humanized TNF-a antibody (Humira) and soluble TNF receptor-II (Enbrel) and are associated with a total cumulative market value of more than $20 billion a year. As well as being expensive ($15 000-20 000 per person per year), these drugs have to be injected and have enough adverse effects to be given a black label warning by the FDA. In the current report, we describe an alternative, curcumin (diferuloylmethane), a component of turmeric (Curcuma longa) that is very inexpensive, orally bioavailable and highly safe in humans, yet can block TNF-a action and production in in vitro models, in animal models and in humans. In addition, we provide evidence for curcumin's activities against all of the diseases for which TNF blockers are currently being used. Mechanisms by which curcumin inhibits the production and the cell signalling pathways activated by this cytokine are also discussed. With health-care costs and safety being major issues today, this golden spice may help provide the solution. LINKED ARTICLESThis article is part of a themed section on Emerging Therapeutic Aspects in Oncology. To view the other articles in this section visit http://dx

show abstract

“…[34][35][36] The main targets include the inflammatory transcription factor NF-jB, inflammatory enzymes (COX-2 and 5-lipoxygenase) and inflammatory cytokines such as TNFa, IL-1, IL-6 and IL-8. 36,37 Dietary curcumin has been shown to alleviate diabetes in high-fat diet-induced obese and leptin-deficient ob/ob mice, 36,37 as indicated by blood glucose levels, insulin tolerance and glycosylated hemoglobin. Mechanisms observed included reduced macrophage infiltration, increased adiponectin production in adipose tissue and decreased hepatic NF-jB activity.…”

Section: Metabolic Dysregulation and Cancermentioning

confidence: 99%

Metabolic regulation and redox activity as mechanisms for angioprevention by dietary phytochemicals

Tosetti

Noonan

Albini

2009

Intl Journal of Cancer

View full text Add to dashboard Cite

The existence of active principles in numerous foods and beverages has been recognized by traditional medicines worldwide after centuries of empirical trial. Epidemiological studies support the concepts linking diet to survival, particularly in the incidence rates of specific cancers. Molecular studies have provided evidence that a wide range of food-derived phytochemicals and other dietassociated compounds or their synthetic derivatives represent a cornucopia of potential new compounds for prevention and treatment of chronic or acute diseases. Many have entered clinical practice or are under clinical testing. A remarkable property shared by several phytochemicals is the capacity to restrain inflammation and angiogenesis, two complex physiologic processes kept under control by strict rules, which can backfire in cancer and in pathologic conditions such as metabolic, cardiovascular and neurological disorders. We termed this concept ''angioprevention''. Here, we discuss recent findings on the metabolic effects of several phytochemicals with anticancer properties. The different molecular targets shared by these compounds seem to converge on crosstalking signaling networks involved in controlling energy metabolism through a redox-regulated code. The redox imbalance produced in the tissue microenvironment elicits an adaptive response that seems to provide cytoprotective effects potentially beneficial in cardiovascular and neurological disorders or energy balancing effects in metabolic disorders. However, in transformed and overt tumor cells, this redox imbalance favors cell death while curbing tumor inflammation and angiogenesis, thus engaging an overall antitumor response. These concepts provide a broader framework for pharmacological application of phytochemical-derived drugs against cancer. ' UICCKey words: chemoprevention; cancer; angiogenesis; inflammation; redox; angioprevention; oxidative stress; aging; longevity The term ''chemoprevention'' was proposed by Sporn 1 more than 30 years ago to describe pharmacologic or dietary interventions that would interfere with the carcinogenic process, resulting in decreased cancer risk, a ''descendent'' of the cancer chemoprophylaxis concept. The scope of dietary cancer prophylaxis is not only to avoid cancer but also to transform overt cancer into a chronic disease. After evidence from empirical traditional medicine and decades of preclinical testing, we are now witnessing clinical application of several dietary phytochemicals in experimental trials of chemoprevention and intervention for solid tumors and hematologic malignancies. About 30 NIH-registered clinical trials are ongoing to test the efficacy of curcumin, a principle contained in turmeric, the yellow component of curry from the rhizome of Curcuma longa L., used as an antiinflammatory agent for centuries in traditional Asian medicine. Ten clinical trials are active for the polyphenol found in red grapes, resveratrol, and nearly 30 studies are using green tea extracts or the active flavonoid component epigalloca...

show abstract

Curcumin Supplementation Lowers TNF-α, IL-6, IL-8, and MCP-1 Secretion in High Glucose-Treated Cultured Monocytes and Blood Levels of TNF-α, IL-6, MCP-1, Glucose, and Glycosylated Hemoglobin in Diabetic Rats

Cited by 251 publications

References 64 publications

Effect of Curcumin and Angiotensin II Receptor Antagonist on Insulin Sensitivity and on Inflammation in Induced Diabetic Rats

Effect of Curcumin and Angiotensin II Receptor Antagonist on Insulin Sensitivity and on Inflammation in Induced Diabetic Rats

Curcumin: an orally bioavailable blocker of TNF and other pro‐inflammatory biomarkers

Metabolic regulation and redox activity as mechanisms for angioprevention by dietary phytochemicals

Contact Info

Product

Resources

About